CARBOGEN AMCIS

Belkins
CARBOGEN AMCIS is a leading provider of drug development and commercialization services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development.

Related News

RX SAVINGS SOLUTIONS ANNOUNCES EXPANSION OF PHARMACY TRANSPARENCY OFFERING TO MID-MARKET ORGANIZATIONS

Prnewswire | May 27, 2020

news image

Rx Savings Solutions announced today its entrance into the mid-market segment with the expansion of their personalized prescription drug transparency program to midsize organizations. With this comprehensive solution driven by more than 29,000 clinical recommendations, more benefit leaders of all sizes can provide a valuable resource for members to engage with personalized savings options. As pharmacy continues to be the most predictable and repeated spend in healthcare, Rx Savings Solutions aim...

Read More

MEDICURE ANNOUNCES TERMINATION OF REDS™ PRO MARKETING AND DISTRIBUTION AGREEMENT

Prnewswire | August 20, 2020

news image

Medicure Inc. a pharmaceutical company, today announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. ("Sensible") for the marketing of the ReDSTM Pro ("ReDS Pro") device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to Medicure for sales to customer leads provided by Medicure. Medicure continues to hold a 7....

Read More

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

HIT Consultant | April 07, 2020

news image

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

EARLY MISSTEPS, TRANSPARENCY QUESTIONS DOG U.S. GOVERNMENT'S REMDESIVIR ROLLOUT: REPORTS

Fiercepharma | May 08, 2020

news image

When there’s only one proven therapy for a global pandemic that’s infected millions—and a limited initial supply—how exactly should officials distribute it? So far, the U.S. government hasn't figured it out, reports say. When Gilead Sciences scored its groundbreaking FDA emergency use authorization for COVID-19 therapy remdesivir, the company made the unusual move of handing distribution rights to the federal government. But the rollout has gotten off to a rocky start...

Read More

Prnewswire | May 27, 2020

news image

RX SAVINGS SOLUTIONS ANNOUNCES EXPANSION OF PHARMACY TRANSPARENCY OFFERING TO MID-MARKET ORGANIZATIONS

Rx Savings Solutions announced today its entrance into the mid-market segment with the expansion of their personalized prescription drug transparency program to midsize organizations. With this comprehensive solution driven by more than 29,000 clinical recommendations, more benefit leaders of all sizes can provide a valuable resource for members to engage with personalized savings options. As pharmacy continues to be the most predictable and repeated spend in healthcare, Rx Savings Solutions aim...

Read More

Prnewswire | August 20, 2020

news image

MEDICURE ANNOUNCES TERMINATION OF REDS™ PRO MARKETING AND DISTRIBUTION AGREEMENT

Medicure Inc. a pharmaceutical company, today announced the termination of the marketing and distribution agreement with Sensible Medical Innovations Inc. ("Sensible") for the marketing of the ReDSTM Pro ("ReDS Pro") device in the United States. In connection with the termination, Sensible and the Company have entered into a transition agreement which provides additional compensation to Medicure for sales to customer leads provided by Medicure. Medicure continues to hold a 7....

Read More

HIT Consultant | April 07, 2020

news image

EXSCIENTIA TO SCREEN 15,000 DRUGS IN SEARCH FOR CORONAVIRUS TREATMENT

Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK’s national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus. Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready molecules, and ...

Read More

Fiercepharma | May 08, 2020

news image

EARLY MISSTEPS, TRANSPARENCY QUESTIONS DOG U.S. GOVERNMENT'S REMDESIVIR ROLLOUT: REPORTS

When there’s only one proven therapy for a global pandemic that’s infected millions—and a limited initial supply—how exactly should officials distribute it? So far, the U.S. government hasn't figured it out, reports say. When Gilead Sciences scored its groundbreaking FDA emergency use authorization for COVID-19 therapy remdesivir, the company made the unusual move of handing distribution rights to the federal government. But the rollout has gotten off to a rocky start...

Read More